XFOR - X4 Pharmaceuticals, Inc

4.19
0.120   2.864%

Share volume: 246,263
Last Updated: 05-01-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$4.07
0.12
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 8%
Dept financing 11%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.48%
1 Month
-1.18%
3 Months
5.28%
6 Months
2.44%
1 Year
12.48%
2 Year
287.96%
Key data
Stock price
$4.19
P/E Ratio 
N/A
DAY RANGE
$4.05 - $4.24
EPS 
-$4.69
52 WEEK RANGE
$1.35 - $4.83
52 WEEK CHANGE
$26.97
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
90.920 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
2.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$414,821
AVERAGE 30 VOLUME 
$387,883
Company detail
CEO: Paula S. Ragan
Region: US
Website: x4pharma.com
Employees: 80
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.

Recent news